November 17, 2026

Comhla’s bid tests control of the entire animal health chain

Close-up of a brown and white dairy cow in a livestock farm pen with ear tags.

Comhla Vet’s bid for Veterinaryfirst is being talked about as a story about independent clinics losing ground to corporates. That is true, but it undersells what is at stake. Comhla already owns drug wholesalers, a dairy nutrition supplier and a diagnostic lab. Add 17 more clinics and the deal becomes a test of whether one group can own most of the animal health value chain in parts of regional New Zealand, and what that does to farm input costs and advice.

Sixty-nine clinics and counting

Comhla owns and operates 52 veterinary clinics nationwide and wants to buy 100% of Veterinaryfirst, which runs 17 clinics under its Petfirst (companion animal) and Farmfirst (production animal) brands. Veterinaryfirst employs 64 vets, 52 of them full-time equivalent. The combined business would be the country’s largest vet network, and Newsroom reports a handful of vets warning that the share of corporate-owned clinics is reaching a level that “could tip the scales towards the demise of the independent vet”.

The growth has been quick. In 2025, Farmers Weekly reported Comhla had more than 300 vets across about 60 clinics in New Zealand and Australia. Just over a year later it has 52 in New Zealand alone.

The supply chain is the real prize

Comhla Group’s wider businesses include wholesalers Fortis Vet and Agilis Vet, Heartland Nutrition, which supplies trace elements, minerals and feed products for dairy cattle, and diagnostic laboratory DRL. That is the detail that turns a clinic roll-up into something bigger.

Taranaki Veterinary Centre, a cooperatively owned practice, spelled out the concern in its submission to the Commerce Commission. After the deal, it argues, Comhla would have influence across importing and procurement, wholesale distribution, clinical services, animal nutrition and lab testing. Comhla-owned clinics could be incentivised to buy through Agilis and Fortis, cutting volumes for rival wholesalers such as Provet and SVS and for manufacturers including Elanco, Virbac, Zoetis, MSD Animal Health, Boehringer Ingelheim and AgriHealth.

For a farmer, this is not abstract. The vet who diagnoses a mineral deficiency, the lab that tests the sample and the company selling the supplement could all sit inside one group. That is not proof of misconduct. It is a structure where the incentive to steer purchasing is obvious, and where it becomes harder for a client to tell independent advice from a sales channel.

Fragmented nationally, monopolised locally

Comhla’s best defence is that the industry is crowded. The Commission counts 603 unique veterinary service businesses in New Zealand as of 2025. Nationally, nobody is close to dominant.

But farmers do not buy vet services nationally. The Commission’s own catchments run 30km for rural companion animal services and 50km for production animals. Across 20 local markets it examined, some reach 100% combined market share: Alexandra and Wanaka for companion animals, and the King Country for both companion and production animal work. A King Country dairy farmer with a down cow at 2am does not care that there are 600 vet businesses elsewhere.

The consolidation trend is not new. In 2025, Farmers Weekly cited an IBISWorld finding of 8.7% fewer clinics in 2024 than in 2023, while then-NZVA president Rob Mills noted that 70% of UK practices are corporate-owned and suggested New Zealand would likely follow.

There is a genuine efficiency case

This is not a simple villain story. The workforce is tight, with 3,152 vets working in 2024 and 201 new registrations that year against a well-publicised shortage. Pooling scarce vets, rosters and back-office support across more clinics can keep rural practices open that might otherwise close. In 2025, Comhla’s then-clinical director Mark Bryan said its model was built for sustainability, with small shareholdings offered to staff to retain them and reward effort. The profession’s body was measured too, with then-NZVA chief executive Kevin Bryant focusing on professional development and support regardless of ownership.

Scale is not the problem. Scale without a competitive check in towns where the merged firm would be the only option is.

What the Commission should do by December

The Commission opened the case on 20 October and is due to decide by 16 December. A pro-competition, pro-market regulator does not need to block the deal outright. It does need to be satisfied on two points: that the 100% local markets are resolved, most likely through divesting clinics in Alexandra, Wanaka and the King Country to independent buyers, and that Comhla’s wholesale and lab arms cannot be used to squeeze rival suppliers out of its clinics.

If the Commission waves this through on national market shares alone, it will have answered the wrong question. Farmers, and the multinationals selling to them, should be watching the local and vertical analysis closely, because that is where their costs will be decided.

Sources

Reader Poll · 6 questions

Do you agree or disagree with the following?

Community

Join the discussion

Add useful context, ask a good question, or challenge an idea — keep it specific and respectful.

Create a commenter account

Enter the name you want shown publicly and your email. We will email you a password-set link; you cannot comment until you use it.

Your email is used for sign-in and account security. It is not published with comments.

Subscribe for weekly news

Subscribe For Weekly News

* indicates required